Clinical Trial Update: A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection [Phase 1]

View source ↗

Summary

Phase 1 randomized study evaluating activity, safety, and tolerance of the oral Tat antagonist Ro 24-7429 in HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ro 24-7429 (Tat antagonist Ro 24-7429)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED